Q1 EPS Forecast for Atossa Therapeutics Lifted by Analyst

Atossa Therapeutics, Inc. (NASDAQ:ATOS) – Investment analysts at HC Wainwright boosted their Q1 2025 earnings per share (EPS) estimates for shares of Atossa Therapeutics in a research report issued on Tuesday, March 25th. HC Wainwright analyst E. Bodnar now anticipates that the company will post earnings of ($0.05) per share for the quarter, up from their prior forecast of ($0.07). HC Wainwright has a “Buy” rating and a $7.00 price objective on the stock. The consensus estimate for Atossa Therapeutics’ current full-year earnings is ($0.22) per share. HC Wainwright also issued estimates for Atossa Therapeutics’ Q2 2025 earnings at ($0.06) EPS, Q3 2025 earnings at ($0.07) EPS, Q4 2025 earnings at ($0.07) EPS, FY2025 earnings at ($0.25) EPS, FY2026 earnings at ($0.30) EPS, FY2028 earnings at ($0.22) EPS and FY2029 earnings at ($0.18) EPS.

Atossa Therapeutics (NASDAQ:ATOS) last issued its earnings results on Tuesday, March 25th. The company reported ($0.05) EPS for the quarter, topping the consensus estimate of ($0.06) by $0.01.

Separately, Ascendiant Capital Markets raised their target price on Atossa Therapeutics from $6.50 to $7.00 and gave the stock a “buy” rating in a research note on Monday, December 9th.

Atossa Therapeutics Trading Down 0.3 %

ATOS stock opened at $0.70 on Friday. The stock has a market capitalization of $89.93 million, a price-to-earnings ratio of -3.16 and a beta of 1.20. The firm’s 50-day moving average price is $0.79 and its two-hundred day moving average price is $1.10. Atossa Therapeutics has a 12-month low of $0.66 and a 12-month high of $2.31.

Institutional Trading of Atossa Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in ATOS. Geode Capital Management LLC increased its position in Atossa Therapeutics by 1.6% during the 3rd quarter. Geode Capital Management LLC now owns 2,814,446 shares of the company’s stock valued at $4,278,000 after purchasing an additional 44,762 shares during the period. State Street Corp increased its position in shares of Atossa Therapeutics by 4.2% during the third quarter. State Street Corp now owns 1,732,221 shares of the company’s stock valued at $2,633,000 after buying an additional 69,180 shares during the period. Renaissance Technologies LLC increased its position in shares of Atossa Therapeutics by 18.9% during the fourth quarter. Renaissance Technologies LLC now owns 1,557,632 shares of the company’s stock valued at $1,471,000 after buying an additional 247,562 shares during the period. Northern Trust Corp raised its stake in Atossa Therapeutics by 7.5% in the fourth quarter. Northern Trust Corp now owns 1,025,724 shares of the company’s stock worth $968,000 after buying an additional 71,525 shares in the last quarter. Finally, JPMorgan Chase & Co. lifted its holdings in Atossa Therapeutics by 141.4% in the fourth quarter. JPMorgan Chase & Co. now owns 361,296 shares of the company’s stock worth $341,000 after buying an additional 211,654 shares during the period. Hedge funds and other institutional investors own 12.74% of the company’s stock.

About Atossa Therapeutics

Atossa Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer.